Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy
- 1 December 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (12) , 1381-9
Abstract
Importance Next-generation sequencing can detect variants of uncertain significance (VUSs), for some of which gene therapy would not be advantageous. Therefore, the pathogenicity of compound heterozygous or homozygous variants should be confirmed before bilateral vitrectomy and administration of voretigene neparvovec-rzyl. Objective To describe an in vitro mutagenesis assay for assessing the pathogenicity of variants in theRPE65gene. Design, Setting, and Participants This case series was conducted at 2 tertiary referral centers. Clinical history, imaging, and electrophysiologic testing results were reviewed from September 5, 2008, to December 31, 2019. Participants were 4 pediatric patients with Leber congenital amaurosis who were evaluated for or met the inclusion criteria for phase 1 to 3 clinical trials or were referred for voretigene neparvovec-rzyl treatment. Main Outcomes and Measures A functional assay was used to confirm the pathogenicity of novelRPE65VUSs in 4 patients with Leber congenital amaurosis. Results Four patients with Leber congenital amaurosis had VUSs inRPE65. Patients 1 and 2 were siblings with the homozygous VUS c.311G>T p.(G104V). Patient 3 was a compound heterozygote with 1 known pathogenic allele, c.1202_1203insCTGG p.(Glu404AlafsTer4), and 1 VUS, c.311G>T p.(G104V), which segregated to separate alleles. Patient 4 was also a compound heterozygote with 1 pathogenic variant, c.11 + 5G>A, and 1 variant intrans, c.1399C>T p.(P467S). In vitro mutagenesis revealed that the G104V and P467S RPE65 proteins were catalytically inactive (0% isomerase activity). Patients 1 and 2 were excluded from participation in a phase 1 trial owing to high Adeno-associated virus 2 capsid-neutralizing antibodies. Patients 3 (G104V) and 4 (P467S) underwent successful surgical gene therapy with voretigene neparvovec-rzyl, and their response to lower white light intensity and visual field increased in fewer than 30 days after gene therapy intervention. Conclusions and Relevance Findings from this study suggest that, in patients with missense mutations inRPE65, functional assays of protein function can be performed to assess the pathogenicity of variants in both compound heterozygous and homozygous cases. Given the potential risks of gene therapy operations, in vitro RPE65 activity testing should be considered to avoid the possibility of treating a false genotype.Keywords
This publication has 40 references indexed in Scilit:
- Predicting the Functional Effect of Amino Acid Substitutions and IndelsPLOS ONE, 2012
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- RPE65, Visual Cycle Retinol Isomerase, Is Not Inherently 11-cis-specificJournal of Biological Chemistry, 2010
- Crystal structure of native RPE65, the retinoid isomerase of the visual cycleProceedings of the National Academy of Sciences, 2009
- Leber congenital amaurosis: Genes, proteins and disease mechanismsProgress in Retinal and Eye Research, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Screening of theRPE65Gene in the Asian Indian Patients with Leber Congenital AmaurosisOphthalmic Genetics, 2008
- Lentiviral Gene Transfer of Rpe65 Rescues Survival and Function of Cones in a Mouse Model of Leber Congenital AmaurosisPLOS Medicine, 2006
- Identification of conserved histidines and glutamic acid as key residues for isomerohydrolase activity of RPE65, an enzyme of the visual cycle in the retinal pigment epitheliumFEBS Letters, 2005
- Homology Modeling2003